Microcap Ledger Bicycle Therapeutics Plc $BCYC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Cambridge, United Kingdom
- Fiscal year end
- December 31
What the company doesAI summary of filing
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle molecules, a novel class of fully synthetic cyclic peptides designed to deliver therapeutic payloads to disease targets. The company makes money through its internal product development programs focused on oncology and through collaboration agreements with biopharmaceutical partners in other therapeutic areas. Its internal pipeline includes drug conjugates (BDC molecules) such as nuzefatide pevedotin in Phase I/II trials, radioconjugates (BRC molecules) in IND-enabling stages, and immune cell agonists in Phase I/II development, with the company currently undergoing a strategic reprioritization to focus on next-generation therapeutics. [10-K 2026-03-17]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $1.52M | −$111.16M | −$115.53M | $510.05M | [10-Q 2026-07-30] |
| FY ended Dec 2025 | $72.59M | −$218.96M | −$249.68M | $628.11M | [10-K 2026-03-17] |
| FY ended Dec 2024 | $35.27M | −$169.03M | −$164.72M | $879.52M | [10-K 2026-03-17] |
- Quarterly cash burn
- −$57.77M
- Cash runway Estimate
- ~26.5 months
Capital structure and dilution
- Shelf registration
- S-3 filed 2025-08-08; declared effective 2025-08-14 [S-3 2025-08-08]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-05 | Skynner Michael | sell | 503 | $3.57 | [4 2026-10-06] |
| 2026-10-05 | Hannay Michael Charles Ferguson | sell | 242 | $3.57 | [4 2026-10-06] |
| 2026-10-05 | Perry Jennifer Scott | sell | 80 | $3.56 | [4 2026-10-06] |
| 2026-10-05 | Perry Jennifer Scott | sell | 326 | $3.78 | [4 2026-10-06] |
| 2026-10-05 | Lee Kevin | sell | 1,638 | $3.57 | [4 2026-10-06] |
| 2026-10-05 | Thompson Travis Alvin | sell | 79 | $3.57 | [4 2026-10-06] |
| 2026-10-02 | Swanton Robert Charles | sell | 3,431 | $3.47 | [4 2026-10-06] |
| 2026-10-02 | Skynner Michael | sell | 1,942 | $3.47 | [4 2026-10-06] |
| 2026-10-02 | Hannay Michael Charles Ferguson | sell | 1,572 | $3.47 | [4 2026-10-06] |
| 2026-10-02 | Perry Jennifer Scott | sell | 1,094 | $3.47 | [4 2026-10-06] |
| 2026-10-02 | Lee Kevin | sell | 6,167 | $3.47 | [4 2026-10-06] |
| 2026-10-02 | Thompson Travis Alvin | sell | 893 | $3.47 | [4 2026-10-06] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-20 | 8-K | Director or officer change |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-30 | 10-Q | Quarterly report |
| 2026-07-30 | 8-K | Results of operations |
| 2026-06-18 | 8-K | Shareholder vote results |
| 2026-05-21 | 8-K | Other events |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-04 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-30 | 10-Q | Quarterly report |
| 2026-04-30 | 8-K | Results of operations |
| 2026-04-22 | DEF 14A | Proxy statement |
Alerts for $BCYC
Email me when Bicycle Therapeutics Plc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.